BayHep B Articles
Cangene gets orphan status for HepaGam
7 April 2008
Germany's Biotest buys Nabi unit for $185M
17 September 2007
FDA clears Cangene's HepaGam B for HBV
16 April 2007
Cangene's HepaGam gets US approval
6 February 2006
Cangene's HepaGam gets US approval
6 February 2006
Nabi's 3rd-qtr 2004 profit takes a dive
25 October 2004
Bayer Biologicals moves to stop counterfeiting
26 July 2004
FDA responds to Nabi's BLA for Nabi-HB
16 June 2003
Bayer retains Canadian blood products supply deal
6 January 2003
Nabi Files IND In USA For Hep B Drug
14 December 1998
Nabi Files IND with FDA For Reformulated Hepatitis B Immune Globulin
19 November 1998
Nabi's H-BIG Gets Priority Review Status From FDA
22 September 1998
Nabi Submit PLA For H-BIG
20 August 1998
Showing 1-13 of 13 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
